NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 123 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,817 | -36.5% | 2,246 | 0.0% | 0.00% | – |
| Q1 2023 | $9,164 | -23.7% | 2,246 | -6.1% | 0.00% | -100.0% |
| Q4 2022 | $12,008 | -61.6% | 2,392 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $31,287 | +2.0% | 2,392 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $30,665 | +16.3% | 2,392 | +38.3% | 0.00% | 0.0% |
| Q1 2022 | $26,367 | -83.9% | 1,729 | -81.3% | 0.00% | -50.0% |
| Q4 2021 | $163,941 | -15.7% | 9,257 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $194,582 | +6.6% | 9,257 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $182,548 | -22.9% | 9,257 | +13.6% | 0.00% | -25.0% |
| Q1 2021 | $236,833 | -6.3% | 8,147 | -2.3% | 0.00% | 0.0% |
| Q4 2020 | $252,691 | +90.4% | 8,341 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $132,705 | -19.4% | 8,341 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $164,651 | +60.1% | 8,341 | 0.0% | 0.00% | +50.0% |
| Q1 2020 | $102,845 | -33.3% | 8,341 | 0.0% | 0.00% | -33.3% |
| Q4 2019 | $154,225 | – | 8,341 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 18,136,735 | $232,513,000 | 49.48% |
| Ponoi II Management, LLC | 1,298,908 | $16,652,000 | 45.25% |
| Ponoi Management, LLC | 1,298,908 | $16,652,000 | 26.29% |
| Euclidean Capital LLC | 746,674 | $9,572,000 | 8.14% |
| StepStone Group LP | 1,573,357 | $20,170,000 | 2.16% |
| First Light Asset Management, LLC | 1,135,884 | $14,562,000 | 1.69% |
| Lexington Partners L.P. | 110,428 | $1,416,000 | 0.73% |
| Rubric Capital Management LP | 797,588 | $10,225,000 | 0.54% |
| Boxer Capital, LLC | 500,000 | $6,410,000 | 0.41% |
| DAFNA Capital Management LLC | 107,653 | $1,380,000 | 0.38% |